A5028675175- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Hepatitis C virus research
- Blood groups and transfusion
- Pneumocystis jirovecii pneumonia detection and treatment
- Sex work and related issues
- Immunodeficiency and Autoimmune Disorders
- Medication Adherence and Compliance
- HIV/AIDS oral health manifestations
- Virology and Viral Diseases
- Herpesvirus Infections and Treatments
- vaccines and immunoinformatics approaches
- Adolescent Sexual and Reproductive Health
- Respiratory and Cough-Related Research
- Healthcare Policy and Management
- Chronic Disease Management Strategies
- Bariatric Surgery and Outcomes
- Respiratory Support and Mechanisms
- Data-Driven Disease Surveillance
- Research on Leishmaniasis Studies
- Glycosylation and Glycoproteins Research
ViiV Healthcare (United Kingdom)
2021-2022
ViiV Healthcare (Spain)
2010-2017
Hôpital Cochin
1998-2014
Maternité Port Royal
2002-2013
Assistance Publique – Hôpitaux de Paris
2008-2009
AstraZeneca (Switzerland)
2005
GlaxoSmithKline (France)
2004
ABSTRACT Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which widely used. We deemed it essential to conduct a wide coordinated survey of emergence ACV-resistant HSV strains . have formed network 15 virology laboratories isolated identified, between May 1999 April 2002, type 1 (HSV-1) HSV-2 hospitalized subjects. The sensitivity each isolate ACV was evaluated by colorimetric test...
Background: To assess HIV burden in both acellular and cellular fractions of semen men with different levels blood plasma RNA by a cross-sectional study. Patients: Fifty-two HIV-1-seropositive (21 receiving antiretroviral therapy) CD4 cell counts ranging from 1 to 1170¥106/l. Methods: Semen was separated into seminal enriched motile spermatozoa or non-spermatozoal cells. quantified the HIV-Monitor technique (Roche) plasma, fractions. DNA infectious virions were detected either PCR...
Objectives A novel long-acting regimen (LAR) of cabotegravir and rilpivirine for HIV treatment requires dosing every 2 months instead daily. We assessed what proportion people living with physicians would be interested in trying offering LAR respectively why. Methods 688 on treatment, 120 completed web-based surveys Germany, Italy, the UK France during 2019. Balanced description a hypothetical regarding efficacy, administration possible side effects were provided. The injections assumed to...
Thirty-nine HIV-1-infected men were prospectively tested for HIV seminal shedding after the initiation of highly active antiretroviral therapy. RNA drastically decreased in semen all men, but low levels remained detectable three at month 18. Proviral DNA became undetectable cells 18 months. HIV-infected male genital compartment may come from intermittent passage blood lymphocytes, rather than constituing a major local reservoir. HIV-1 is recovered as free particles (HIV RNA) plasma and...
Background The pregnancy-related adverse effects of antiretroviral therapy (ART) have yielded discordant results, which could be explained in part by the heterogeneity ART protocols. objective our study was to explore whether lopinavir/ritonavir (LPV/r) exposure during pregnancy is associated with outcomes. Methods Data on 100 consecutive HIV type-1 (HIV-1)-infected women receiving LPV/r and who delivered after 15 weeks gestational age (GA) between January 2003 June 2007 a single centre were...
A live recombinant canarypox vector expressing HIV-1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection their safety and immunogenicity. Both antigens were well tolerated. ALVACHIV (vCP205) induced levels of neutralizing antibodies against 33% the volunteers. None them had detectable nonsyncytium-inducing clade B primary isolate (Bx08). After fourth injection vCP205, CTL...
We compared IgG and IgA distribution in serum, three different salivary samples, two rectal secretion cervicovaginal secretions, seminal secretions from asymptomatic CDC stage II/III HIV-1-infected subjects (n = 44) HIV-1-seronegative volunteers 52). In-house ELISAs were used to measure total levels, as well HIV-specific anti-gp120 MN anti-p24 LAI IgA. Human serum albumin was titrated parallel calculate the relative coefficient of excretion (RCE). In spite substantial interindividual...
We measured total IgG 1, IgG2, IgG3, and 4 concentrations by ELISA in serum (S), saliva (TS), cervicovaginal secretions (CVS), seminal (SPE), rectal (RS) from either CDC II/III HIV1-infected subjects or healthy volunteers. Human albumin was parallel to calculate the relative coefficient of excretion (RCE). Levels 1 3 directed against gp120 MN also were all samples, specific activity (SA) calculated. HIV-1-specific IgG2 not compared, as 2 IgG4 levels HIV-1-infected found be lower than...
To investigate the possible necessity of an increase in lopinavir dose during pregnancy order to achieve concentrations previously defined as predictive virological efficacy.Lopinavir pharmacokinetics were investigated by a population approach performed on 145 HIV-infected women, including 74 pregnant women. The final model was used determine probability achievement target trough Monte Carlo simulations.The typical estimates (inter-individual variability %) apparent clearance (CL/F) and...
Objectives: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) explore satisfaction adherence current ART. Patients methods: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an quantitative part estimated the strength preference different using online discrete choice experiment (DCE). DCE data analyzed mixed logit regression model. Qualitative collected through...
Abstract Background The daily oral dosing requirement for antiretroviral therapy (ART) may be challenging some people living with HIV (PLWHIV) comorbid conditions, confidentiality concerns or pill fatigue. We investigated suboptimal adherence from the perspective of PLWHIV and physicians. Methods on ART (n = 688) physicians 120) were surveyed during 2019 in France, Germany, Italy UK. Suboptimal was a report participant missed taking their dose as prescribed ‘Sometimes’/‘Often’/‘Very often’....
1. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679-690. doi:10.1001/jama.296.6.679 CrossRef Google Scholar
To estimate the number of patients hospitalized for HIV-related reasons in France, to describe their characteristics and hospitalization-associated costs.A retrospective analysis French hospital medical information database (Programme de médicalisation des systèmes d'information en médecine, chirurgie, obstétrique et odontologie database).Patients with HIV France 2013 2014 were identified through International Classification Diseases, 10th revision diagnostic codes as well comorbidities...
Objectives To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis Monte Carlo Individual Simulation (ARAMIS) model. Methods ARAMIS is microsimulation Markov model lifetime time horizon monthly cycle length. Health states are defined as or without...
To evaluate the cost-effectiveness of an integrase inhibitor (INI), dolutegravir (DTG), in combination with abacavir (ABC)/lamivudine (3TC) France, treatment-naive (TN) HIV adult patients.The ARAMIS microsimulation Markov model, evaluates costs and effects DTG vs. first-line ARVs options including INIs (raltegravir, elvitegravir/c), protease inhibitors (PIs) (darunavir/r, atazanavir/r, lopinavir/r), non-nucleoside reverse transcriptase (efavirenz rilpivirine). Efficacy safety data were...